Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same ...

PRAGUE & AMSTERDAM, March 13, 2025--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license ...

PRAGUE--(BUSINESS WIRE)--SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, today announced a license and option agreement with Synaffix B.V., a Lonza company, to develop ...

SOTIO Biotech (SOTIO) is shaping the future of targeted cancer therapies by translating compelling science into patient benefit. The SOTIO pipeline includes three clinical-stage programs: SOT102, a ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the promotion of Vivi Boura, M.D., Ph.D., an accomplished oncologist with extensive experience leading the ...

SOTIO Strengthens Leadership Team with Appointments of Amy Jensen-Smith as Chief Scientific Officer and Ulrich Moebius as Chief Development Officer SOTIO Biotech, a clinical-stage biopharmaceutical ...

Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that ...

PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase ...

PPF Group provides funding to advance SOTIO through key clinical milestones Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial Three ...

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline PRAGUE & AMSTERDAM--(BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage ...

SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need Collaboration bolsters SOTIO’s wider ...